汉森制药(002412) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 31,523,068.60, an increase of 0.37% year-on-year[7]. - Operating revenue for the reporting period was CNY 210,165,433.40, representing a growth of 4.21% compared to the same period last year[7]. - Basic earnings per share were CNY 0.0626, reflecting a slight increase of 0.32% compared to the previous year[7]. - The weighted average return on equity was 2.01%, a decrease of 0.14% from the previous year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,070,607.76, a decrease of 18.44% year-on-year[7]. - The total profit for the third quarter was CNY 30,897,974.75, compared to CNY 37,469,661.10 in the same quarter last year, indicating a decline of approximately 17.6%[44]. - The net profit for the third quarter was CNY 31,523,068.60, slightly up from CNY 31,405,807.94 year-over-year, indicating a stable performance[44]. - The comprehensive income totalled CNY 27,945,659.86, down from CNY 28,676,195.09 in the previous year, showing a decrease of about 2.5%[45]. - The total profit for the third quarter was CNY 95,303,572.66, down 23.5% from CNY 124,501,789.52 year-over-year[52]. Cash Flow - The net cash flow from operating activities was CNY 81,067,442.42, an increase of 19.66% year-on-year[7]. - The net cash flow from operating activities was 118,799,257.13 CNY, a decrease of 1.04% compared to 121,055,667.96 CNY in the previous period[62]. - The total cash inflow from investment activities was 10,216,295.00 CNY, while cash outflow was 29,896,498.90 CNY, resulting in a net cash flow of -19,680,203.90 CNY, an improvement from -41,553,427.00 CNY in the previous period[63]. - The net cash flow from financing activities decreased by CNY 46,579,960.34, a decline of 98.37%, mainly due to cash dividends paid during the period[15]. - The net cash flow from financing activities was -93,931,660.42 CNY, compared to -47,351,700.08 CNY in the previous period, indicating increased cash outflows for debt repayment and interest payments[63]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,838,835,275.85, a decrease of 2.34% compared to the end of the previous year[7]. - The company's current assets totaled CNY 529,075,303.09, down from CNY 593,861,751.70 at the end of 2019, indicating a decline of approximately 10.9%[33]. - The total liabilities of the company were not explicitly stated, but the decrease in current liabilities can be inferred from the reduction in short-term borrowings and accounts payable[34]. - Total liabilities amounted to CNY 352,928,115.87, with current liabilities at CNY 336,524,092.92 and non-current liabilities at CNY 16,404,022.95[72]. - The total equity attributable to shareholders reached CNY 1,529,977,688.84, with retained earnings of CNY 733,653,864.39[72]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,558[11]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares[11]. Investments and Expenses - The company reported non-recurring gains of CNY 8,097,431.74 during the reporting period[8]. - Research and development expenses increased to CNY 8,680,853.06 from CNY 6,294,832.50[43]. - Research and development expenses increased to CNY 21,951,717.63, up 10.2% from CNY 19,926,110.91 year-over-year[52]. - The company reported an increase in investment income to CNY 12,729,073.10 from CNY 10,708,645.42, representing a growth of about 18.8% year-over-year[48]. Other Financial Metrics - Other receivables increased by CNY 10,042,553.08, a growth of 597.77%, mainly due to loans to Changsha Sanyin Real Estate Development Co., Ltd.[15]. - Other current assets decreased by CNY 25,897,445.17, a decline of 65.31%, primarily due to reduced financial product purchases by Yunnan Yongzitang Pharmaceutical Co., Ltd.[15]. - Financial expenses decreased by CNY 3,022,500.64, a decline of 37.48%, due to reduced bank loans and corresponding interest expenses.[15]. - The company experienced a credit impairment loss of CNY 1,042,850.64, compared to a gain of CNY 583,998.45 in the previous year[52].